Extended stability data for the reference Herceptin have been published, supporting advanced preparation and dose banding. Given stability data for SB3 are limited, a new study sought to assess the extended physiochemical stability and bioactivity of the biosimilar and to evaluate the advanced preparation of the reconstituted and diluted product.
Samsung Bioepis’ SB3, approved under the name Ontruzant in the United States and European Union, is a biosimilar trastuzumab referencing Herceptin.
Like that of its reference, SB3’s product information highlights the need for aseptic conditions during handling, as the product is for a single use and does not contain a preservative. Under aseptic conditions, SB3, like Herceptin, is physically and chemically stable for 48 hours after reconstitution with sterile water and stored at 2°C to 8°C. Diluted SB3 is also physically and chemically stable for 24 hours up to 30°C when stored in in polyvinylchloride, polyethylene, or polypropylene bags containing 0.9% normal saline.
Extended stability data for the reference Herceptin have been published, supporting advanced preparation and dose banding. Given stability data for SB3 are limited, a new study, published in Advances in Therapy, sought to assess the extended physiochemical stability and bioactivity of the biosimilar and to evaluate the advanced preparation of the reconstituted and diluted product.
Under controlled, aseptic conditions, researchers assessed the stability of reconstituted and diluted SB3 according to UK National Health Service guidance, then stored the reconstituted product at 25°C  (± 2°C) with 60% (±5%) relative humidity for 3 days. Next, diluted SB3 was stored in an infusion bags in the absence of light at 25°C  (±2°C) with 60% (±5%) relative humidity for 28 days, and 5°C (±3°C) for 28 days, respectively.
Then, physiochemical stability, biological activity, and properties that could impact safety—such as subvisible particulates or submicronic aggregation) were determined.
The investigators found no signs of physiochemical instability or any changes in biological activity for either reconstituted or diluted biosimilar up to day 28. No major change was observed in the proportion of molecular weight variants or relative percentages of acidic, main, and basic charge isoforms of the protein. No increases in particulate or aggregates that could impact safety were noted.
Furthermore, the study included an evaluation of samples at 1 time point beyond the proposed storage period of 28 days; at 33 days of additional storage, the proportion of high molecular weight impurity was not changed.
These findings, write the researchers, further support the physicochemical stability and maintained biological activity of reconstituted SB3 under proper storage conditions, and may help reduce the need to discard unused SB3 doses and to allow for advanced preparation without impacting the quality or biological activity of the product.
Reference
Yun J, Kim J, Chung J, Hwang SJ, Park SJ. Extended stability of reconstituted and diluted SB3 (trastuzumab biosimilar) assessed by physiochemical and biological properties [published online May 17, 2019]. Adv Ther. doi: 10.1007/s12325-019-00973-y.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Breaking Down Biosimilar Barriers: Payer and PBM Policies
November 13th 2024Part 2 of this series for Global Biosimilars Week dives into the complexities of payer and pharmacy benefit manager (PBM) policies, how they impact biosimilar accessibility, and how addressing these issues may look under a second Trump term.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.
Competitive Pricing in Biosimilars: How Adalimumab Could Shape the Industry
Published: October 29th 2024 | Updated: October 29th 2024Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited patients and the health care sector.